The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans

Loo, Yueh–Ming; M. McTamney, Patrick; H. Arends, Rosalinda; E. Abram, Michael; A. Aksyuk, Anastasia; Diallo, Seme; J. Flores, Daniel; J. Kelly, Elizabeth; Ren, Kuishu; Roque, Richard; Rosenthal, Kim; Streicher, Katie; M. Tuffy, Kevin; J. Bond, Nicholas; Cornwell, Owen; Bouquet, Jérôme; Cheng, Lily; Dunyak, James; Huang, Yue; I. Rosenbaum, Anton; Pilla Reddy, Venkatesh; Andersen, Hanné; H. Carnahan, Robert; E. Crowe, James; I. Kuehne, Ana; S Herbert, Andrew; M. Dye, John; Bright, Helen; L. Kallewaard, Nicole; N. Pangalos, Menelas; T. Esser, Mark

doi:10.1126/scitranslmed.abl8124

Public

The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans

Published in Science Translational Medicine • Jan 25, 2022

Authors:

Yueh–Ming Loo

Patrick M. McTamney

Rosalinda H. Arends

Abstract

Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines, there remains a need for more prevention and treatment options for individuals remaining at risk of coronavirus disease 2019 (COVID-19). Monoclonal antibodies (mAbs) against the viral spike protein have pot...

Subject

Monoclonal antibody

Virology

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!